{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:28:50Z","timestamp":1767850130997,"version":"3.49.0"},"reference-count":18,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Malignant pleural effusion (MPE) is a common condition that presents with progressive breathlessness. Long term solutions are often required due to recurrence of effusion after simple drainage. Pleurodesis is one of the main options resorted to for long term control of MPE. There is data to suggest there may be a survival benefit for patients with MPE who achieve successful pleurodesis. A systematic review was carried out to explore this correlation and results suggest that there could be a survival difference according to pleurodesis outcome in patients with MPE. Fifteen studies (reported in 13 papers) were included; 13 (86.6%) of the studies showed survival difference in favour of pleurodesis success. The median [interquartile range] difference in survival between the two groups among the different studies was five [3.5\u20135.8] months. Most of the included studies suffered moderate to severe risk of bias and, thus, large prospective studies of patients undergoing pleurodesis are required to ascertain this effect.<\/jats:p>","DOI":"10.1515\/pp-2020-0147","type":"journal-article","created":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T07:57:24Z","timestamp":1614758244000},"page":"1-5","source":"Crossref","is-referenced-by-count":11,"title":["Survival and pleurodesis outcome in patients with malignant pleural effusion\u00a0\u2013 a systematic review"],"prefix":"10.1515","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8768-6548","authenticated-orcid":false,"given":"Maged","family":"Hassan","sequence":"first","affiliation":[{"name":"Chest Diseases Department , Alexandria Faculty of Medicine , Alexandria , Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elinor","family":"Harriss","sequence":"additional","affiliation":[{"name":"Bodleian Health Care Libraries , University of Oxford , Oxford , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel M.","family":"Mercer","sequence":"additional","affiliation":[{"name":"Oxford Respiratory Trials Unit , University of Oxford , Oxford , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Najib M.","family":"Rahman","sequence":"additional","affiliation":[{"name":"Oxford Respiratory Trials Unit , University of Oxford , Oxford , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2021,2,8]]},"reference":[{"key":"2025120909232008937_j_pp-2020-0147_ref_001_w2aab3b7c19b1b6b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Mierzejewski, M, Korczynski, P, Krenke, R, Janssen, JP. Chemical pleurodesis \u2013 a review of mechanisms involved in pleural space obliteration. Respir Res 2019;20:247. https:\/\/doi.org\/10.1186\/s12931-019-1204-x.","DOI":"10.1186\/s12931-019-1204-x"},{"key":"2025120909232008937_j_pp-2020-0147_ref_002_w2aab3b7c19b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Bibby, AC, Dorn, P, Psallidas, I, Porcel, JM, Janssen, J, Froudarakis, M, et al.. ERS\/EACTS statement on the management of malignant pleural effusions. Eur Respir J 2018;52:1800349. https:\/\/doi.org\/10.1183\/13993003.00349-2018.","DOI":"10.1183\/13993003.00349-2018"},{"key":"2025120909232008937_j_pp-2020-0147_ref_003_w2aab3b7c19b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Hirata, T, Yonemori, K, Hirakawa, A, Shimizu, C, Tamura, K, Ando, M, et al.. Efficacy of pleurodesis for malignant pleural effusions in breast cancer patients. Eur Respir J 2011;38:1425\u201330. https:\/\/doi.org\/10.1183\/09031936.00171610.","DOI":"10.1183\/09031936.00171610"},{"key":"2025120909232008937_j_pp-2020-0147_ref_004_w2aab3b7c19b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Hassan, M, Mercer, RM, Maskell, NA, Asciak, R, McCracken, DJ, Bedawi, EO, et al.. Survival in patients with malignant pleural effusion undergoing talc pleurodesis. Lung Canc 2019;137:14\u20138. https:\/\/doi.org\/10.1016\/j.lungcan.2019.09.003.","DOI":"10.1016\/j.lungcan.2019.09.003"},{"key":"2025120909232008937_j_pp-2020-0147_ref_005_w2aab3b7c19b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Hassan, M, Gadallah, M, Mercer, RM, Harriss, E, Rahman, NM. Predictors of outcome of pleurodesis in patients with malignant pleural effusion: a systematic review and meta-analysis. Expert Rev Respir Med 2020;14:645\u201354. https:\/\/doi.org\/10.1080\/17476348.2020.1746647.","DOI":"10.1080\/17476348.2020.1746647"},{"key":"2025120909232008937_j_pp-2020-0147_ref_006_w2aab3b7c19b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Viallat, JR, Rey, F, Astoul, P, Boutin, C. Thoracoscopic talc poudrage pleurodesis for malignant effusions. A review of 360 cases. Chest 1996;110:1387\u201393. https:\/\/doi.org\/10.1378\/chest.110.6.1387.","DOI":"10.1378\/chest.110.6.1387"},{"key":"2025120909232008937_j_pp-2020-0147_ref_007_w2aab3b7c19b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Kolschmann, S, Ballin, A, Gillissen, A. Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions. Chest 2005;128:1431\u20135. https:\/\/doi.org\/10.1378\/chest.128.3.1431.","DOI":"10.1378\/chest.128.3.1431"},{"key":"2025120909232008937_j_pp-2020-0147_ref_008_w2aab3b7c19b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Trotter, D, Aly, A, Siu, L, Knight, S. Video-assisted thoracoscopic (VATS) pleurodesis for malignant effusion: an Australian Teaching Hospital\u2019s experience. Heart Lung Circ 2005;14:93\u20137. https:\/\/doi.org\/10.1016\/j.hlc.2005.02.004.","DOI":"10.1016\/j.hlc.2005.02.004"},{"key":"2025120909232008937_j_pp-2020-0147_ref_009_w2aab3b7c19b1b6b1ab2b1b9Aa","unstructured":"Ak, G, Metinta\u015f, M, Yildirim, H, Metinta\u015f, S, D\u00fcndar, E, Erginel, S, et al.. Pleurodesis in follow-up and treatment of malignant pleural mesothelioma patients. Tuberk Toraks 2009;57:22\u201331."},{"key":"2025120909232008937_j_pp-2020-0147_ref_010_w2aab3b7c19b1b6b1ab2b1c10Aa","unstructured":"Nikbakhsh, N, Pourhasan Amiri, A, Hoseinzadeh, D. Bleomycin in the treatment of 50 cases with malignant pleural effusion. Caspian J Intern Med 2011;2:274\u20138."},{"key":"2025120909232008937_j_pp-2020-0147_ref_011_w2aab3b7c19b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Rena, O, Boldorini, R, Papalia, E, Mezzapelle, R, Baietto, G, Roncon, A, et al.. Persistent lung expansion after pleural talc poudrage in non-surgically resected malignant pleural mesothelioma. Ann Thorac Surg 2015;99:1177\u201383. https:\/\/doi.org\/10.1016\/j.athoracsur.2014.11.050.","DOI":"10.1016\/j.athoracsur.2014.11.050"},{"key":"2025120909232008937_j_pp-2020-0147_ref_012_w2aab3b7c19b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Hsu, L-H, Hsu, P-C, Liao, T-L, Feng, A-C, Chu, N-M, Kao, S-H. Pleural fluid osteopontin, vascular endothelial growth factor, and urokinase-type plasminogen activator levels as predictors of pleurodesis outcome and prognosticators in patients with malignant pleural effusion: a prospective cohort study. BMC Canc 2016;16:463. https:\/\/doi.org\/10.1186\/s12885-016-2529-1.","DOI":"10.1186\/s12885-016-2529-1"},{"key":"2025120909232008937_j_pp-2020-0147_ref_013_w2aab3b7c19b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Stefani, A, Natali, P, Casali, C, Morandi, U. Talc poudrage versus talc slurry in the treatment of malignant pleural effusion. Eu J Cardiothorac Surg 2006;30:827\u201332. https:\/\/doi.org\/10.1016\/j.ejcts.2006.10.002.","DOI":"10.1016\/j.ejcts.2006.10.002"},{"key":"2025120909232008937_j_pp-2020-0147_ref_014_w2aab3b7c19b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Santos, PS, Marques, MA, Cruz, C, Monteiro, H, Fradinho, F. Predictors of talc slurry pleurodesis success in patients with malignant pleural effusions. Rev Port Pneumol 2017;23:216\u201320. https:\/\/doi.org\/10.1016\/j.rppnen.2017.01.008.","DOI":"10.1016\/j.rppnen.2017.01.008"},{"key":"2025120909232008937_j_pp-2020-0147_ref_015_w2aab3b7c19b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Hsu, LH, Feng, AC, Soong, TC, Ko, JS, Chu, NM, Lin, YF, et al.. Clinical outcomes of chemical pleurodesis using a minocycline. Ther Adv Respir Dis 2019;13:175346661984123. https:\/\/doi.org\/10.1177\/1753466619841231.","DOI":"10.1177\/1753466619841231"},{"key":"2025120909232008937_j_pp-2020-0147_ref_016_w2aab3b7c19b1b6b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Love, D, White, D, Kiroff, G. Thoracoscopic talc pleurodesis for malignant pleural effusion. ANZ J Surg 2003;73:19\u201322.","DOI":"10.1046\/j.1445-2197.2003.02616.x"},{"key":"2025120909232008937_j_pp-2020-0147_ref_017_w2aab3b7c19b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Leemans, J, Dooms, C, Ninane, V, Yserbyt, J. Success rate of medical thoracoscopy and talc pleurodesis in malignant pleurisy: a single-centre experience: pleurodesis in malignant pleurisy. Respirology 2018;23:613\u20137. https:\/\/doi.org\/10.1111\/resp.13252.","DOI":"10.1111\/resp.13252"},{"key":"2025120909232008937_j_pp-2020-0147_ref_018_w2aab3b7c19b1b6b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"Cheah, HM, Lansley, SM, Varano della Vergiliana, JF, et al.. Malignant pleural fluid from mesothelioma has potent biological activities: biological capabilities of pleural fluid. Respirology 2017;22:192\u20139. https:\/\/doi.org\/10.1111\/resp.12874.","DOI":"10.1111\/resp.12874"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2020-0147\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2020-0147\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:00:51Z","timestamp":1765278051000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2020-0147\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,8]]},"references-count":18,"aliases":["10.1515\/pap-2020-0147"],"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12,29]]},"published-print":{"date-parts":[[2021,2,26]]}},"alternative-id":["10.1515\/pp-2020-0147"],"URL":"https:\/\/doi.org\/10.1515\/pp-2020-0147","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"value":"2364-768X","type":"electronic"},{"value":"2364-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,8]]}}}